CTCA has joined hands with Allscripts Sunrise and NantHealth to roll out the Clinical Pathways program. The program will link up NantHealth’s eviti® solutions and Allscript’s electronic health record (HER), thus enhancing an efficient cancer treatment process and smooth delivery of clinical services by medical practitioners. NantHealth brought with it a clinical operating system, NantOS that incorporates a database for cancer care.
Benefits to Patients
As stated in this article, Clinical Pathways will integrate a compilation of cancer research reports from oncologists drawn from across the United States and beyond. These reports improve cancer treatment, which makes them the best patient-centered medical advancement in the recent times. This integration will also link up patients and medical practitioners as well as individual partner patients with the clinical teams that they may require. With this kind of partnership, patients will have a clear understanding of their diagnosis and treatment process. On top of that, Clinical Pathways will provide patient treatment data to health insurance providers to hasten insurance approval when the need arises. Patients at any of the five CTCA hospitals will have access to these services.
Benefits to Physicians
According to Wikipedia, physicians will also have their fair share of benefits from Clinical Pathways. The program will offer them a platform to solicit reliable and accurate medical information from Evidence-Based Medical Library. The library has more than 2,700 cancer treatment prescriptions and regimens compiled from government agencies and oncology associations. These regimens details expected treatment costs and clinical outcomes.
CTCA is a conglomeration of five hospitals that specializes in cancer treatment across the U.S. Founded by Richard Stephenson in 1988, the organization was initially headquartered in Illinois but was later moved to Boca Raton, Florida.
During the first 17 years, the organization was operating in only one hospital: the Midwestern Regional Medical Center in Illinois. The other four hospitals have been established in four different states, including Pennsylvania, Oklahoma, Arizona, and Georgia.
Dr. Scott Rocklage is a trained chemist and a leader of 5 AM Ventures’ management committee. He joined the 5 AM Ventures’ leadership team as a partner and worked his way up to the senior partner post. Dr. Rocklage majored in chemistry during his bachelor’s degree level at the University of California. He undertook his Ph.D. at Massachusetts Institute of Technology. While conducting his doctoral studies, he worked in the lab of the Nobel Prize honoree Richard Schrock. Dr. Rocklage is married to Patty Rocklage, who is an accomplished marriage and family counselor. They live together in Sudbury, Massachusetts.
Dr. Rocklage’s career history, contributions, and achievements
Dr. Rocklage is a seasoned scientist with an extensive experience in the field of research. At the start of his career, he held various management positions in different pharmaceutical firms. Dr. Rocklage was the senior principal of EPIRUS Pharmaceuticals, Inc. He was also the CEO of Amersham Health, Ilypsa Inc., Cubist Pharmaceuticals, and Nycomed Salutar Inc. Dr. Rocklage began working with Nycomed in 1992 as its executive officer. He later became president and the board chairperson of the company. Dr. Rocklage is a committed member of the Board of Cidara Therapeutics Inc., Novira Therapeutics Inc., Rennovia Inc., Pulmatrix Inc., and Kinestral Inc. He guides companies like WaveRx, Whitehead Institute, and Semprus by serving as a board member
Dr. Scott Rocklage recently donated a huge lump sum of cash to his former college to aid in the construction of high-tech laboratories. Dr. Rocklage and his wife gave out $250,000 to assist with the renovation costs. After the construction was complete, they were celebrated during the commissioning of the buildings. Dr. Rocklage and his wife took a tour around the labs together with Bawendi and his students. They were paid tribute by Sylvia Ceyer and her colleagues at the Department of Chemistry. Throughout his career, Dr. Rocklage has acquired extensive work experience in the fields of science, research, management and leadership. Dr. Rocklage has assisted in the development and licensing of over 30 U.S. patents. He has also published over 100 peer-reviewed articles.